ClinicalTrials.gg
CompletedNCT01981850Updated Jan 5, 2022Results posted

A Phase 2 Study of RO7490677 In Participants With Myelofibrosis

A Phase 2 interventional study of RO7490677 and Ruxolitinib in Primary Myelofibrosis, Polycythemia Vera and Post-Essential Thrombocythemia Myelofibrosis, sponsored by Hoffmann-La Roche. Completed at 23 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-01-05.

Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
125
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 454 studies in Primary Myelofibrosis with a site in United States — 70 open to participants now, 105 under way, 12 of them phase 3. Primary Myelofibrosis · United States.

Enrollment
69th of 388
125 · median 40
Started
2013
with 10 others
Phase 2
167 of 454
19 open now
Registered
252nd of 454
by date

Among the 454 studies in Primary Myelofibrosis with a site in United States, this one is the 69th largest by enrollment of the 388 interventional ones that give a count, is one of 11 that started in 2013, is one of 167 in phase 2, and was the 252nd registered.

Primary Myelofibrosis

628 studies on the registry are indexed under Primary Myelofibrosis; 126 are open to participants now.

Browse Primary Myelofibrosis studies →

Open to participants now

70 of the 454 studies in Primary Myelofibrosis with a site in United States are open now. Recruiting first, the newest first:

65 more — sign in →

All 70 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 102 Primary Myelofibrosis studies recruiting now, 84 (82%) set no upper age limit and 13 (13%) stop at 75 or younger; 11 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 454 studies in Primary Myelofibrosis with a site in United States, or all of them as a file.
02

Study summary

RO7490677 is an investigational drug that is being developed for possible use in the treatment of myelofibrosis (MF), a disease in which the bone marrow, which is the organ in the body that makes blood cells, is replaced by fibrosis, or excess scar tissue.

The purpose of this study is to gather information on whether RO7490677 has an effect on the MF disease, whether it is safe in patients with MF, and how well it is tolerated.

Read the detailed description

Stage 1 of this study has completed. Stage 1 was an open-label, Simon two stage, Phase 2 study to determine the efficacy and safety of two different dose schedules of RO7490677 in participants with PMF and post ET/PV MF. There were two treatment cohorts, each assigned to one of two dose schedules receiving either single-agent RO7490677 or RO7490677 in combination with ruxolitinib. Participants were assigned to a weekly or every four week dosing schedule by the investigator.

Stage 2 is a randomized, double-blind Phase 2 study to determine the efficacy and safety of three different doses of RO7490677 in participants with PMF and post ET/PV MF. Participants will be randomized to one of three doses: 0.3 mg/kg, 3.0 mg/kg or 10 mg/kg of RO7490677. This is the second stage of an adaptive design study as defined in FDA Draft Guidance for Industry: Adaptive Design Clinical Trials for Drugs and Biologics, February 2010. Modifications to dose levels, schedule, and regimen have been made in Stage 2 based on data from Stage 1.

03

Conditions studied

  • Primary Myelofibrosis
  • Polycythemia Vera
  • Post-Essential Thrombocythemia Myelofibrosis

Keywords

  • fibrosis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants must be ≥18 years of age at the time of signing the Form (ICF);
  2. Participants must voluntarily sign an ICF;
  3. Participants must have a confirmed diagnosis of PMF as per the WHO diagnostic criteria or post ET/PV MF;
  4. At least Grade 2 marrow fibrosis according to the WHO Grading of Bone Marrow Fibrosis;
  5. Intermediate-1, intermediate -2, or high risk disease according to the IWG -MRT Dynamic International Prognostic Scoring System
  6. A bone marrow must be performed within four weeks prior to Cycle 1 Day 1 treatment to establish the baseline fibrosis score;
  7. Participants must not be candidates for ruxolitinib based on EITHER:

    1. count \< 50 x 10e9/L, OR
    2. \< 100 g/L, have received ≥ 2 units PRBC in the 12 weeks prior to study entry, and be intolerant of or had inadequate response to ruxolitinib;
  8. Participants must have an (ECOG) Performance Status of 0-2. (Appendix F);
  9. of at least twelve months;
  10. At least four weeks must have elapsed between the last dose of any MF- directed drug treatments for myelofibrosis (including therapies) and study enrollment;
  11. Recovery to ≤ Grade 1 or baseline of any toxicities due to prior systemic treatments, excluding alopecia;
  12. Women of child bearing potential (WCBP), defined as a sexually mature woman not surgically sterilized or not for at least 24 consecutive months if ≤55 years or 12 months if >55 years, must have a negative serum pregnancy test within four weeks prior to the first dose of study drug and must agree to use adequate methods of throughout the study. Adequate methods of contraception are outlined in the protocol.
  13. Ability to adhere to the study visit schedule and all protocol requirements;
  14. Must have adequate organ function as demonstrated by the following:

    • (SGPT) and/or AST (SGOT) ≤ 3x (ULN), or ≤ 4 x ULN (if upon judgment of the treating physician, it is believed to be due to extramedullary hematopoiesis [EMH] related to MF);
    • Direct ≤ 1.5 x ULN; or ≤ 2x ULN (if upon judgment of the treating physician, it is believed to be due to EMH related to MF);
    • Serum creatinine ≤ 2.5 mg/dL x ULN.

Exclusion criteria

Exclusion Criteria:

  1. White blood cell count > 25 x 10e9/L or > 10% peripheral blood blasts;
  2. Other invasive within the last 3 years, except non- melanoma skin cancer and localized cured prostate and cervical cancer;
  3. History of stroke, unstable angina, myocardial infarction, or ventricular arrhythmia requiring medication or mechanical control within the last 6 months;
  4. Presence of active serious infection;
  5. Any serious, unstable medical or psychiatric condition that would prevent, (as judged by the Investigator) the participant from signing the form or any condition, including the presence of laboratory abnormalities, which places the participant at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study;
  6. Known history of (HIV), or known active hepatitis A, B, or C infection;
  7. Organ transplant recipients other than bone marrow transplant;
  8. Women who are pregnant or lactating.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
125 participants (actual)

Study arms

  • Experimental
    Stage 1: Cohort 1 Weekly

    Participants who received no treatment for MF in at least two weeks will be assigned to treatment with single agent RO7490677 at a dose of 10 mg/kg IV on Days 1, 3, 5, 8, 15, and 22 of Cycle 1 and Days 1, 8, 15 and 22 of each subsequent 28 day cycle for six cycles.

    Biological: RO7490677

  • Experimental
    Stage 1: Cohort 1 Every 4 Weeks

    Paricipants who received no treatment for MF in at least two weeks will be assigned to treatment with single agent RO7490677 at a dose of 10 mg/kg administered IV on Days 1, 3, and 5 of Cycle 1 and Day 1 of each subsequent 28 day cycle for six cycles.

    Biological: RO7490677

  • Experimental
    Stage 1: Cohort 2 Weekly

    Participants on a stable dose of ruxolitinib for at least 12 weeks, with no improvement in spleen during the last four weeks will be assigned to receive RO7490677 in combination with ruxolitinib at a dose of 10 mg/kg administered IV on Days 1, 3, 5, 8, 15, and 22 of Cycle 1 and Days 1, 8, 15 and 22 of each subsequent 28 day cycle for six cycles.

    Biological: RO7490677 · Drug: Ruxolitinib

  • Experimental
    Stage 1: Cohort 2 Every 4 Weeks

    Participants on a stable dose of ruxolitinib for at least 12 weeks, with no improvement in spleen during the last four weeks will be assigned to receive RO7490677 in combination with ruxolitinib at a dose of 10 mg/kg administered IV on Days 1, 3, and 5 of Cycle 1 and Day 1 of each subsequent 28 day cycle for six cycles.

    Biological: RO7490677 · Drug: Ruxolitinib

  • Experimental
    Stage 2: Cohort 1 0.3mg/kg Every 4 Weeks

    Participants will be treated with single agent RO7490677 at a dose of 0.3 mg/kg IV administered as a 60 minute intravenous infusion on Days 1, 3, and 5 of Cycle 1 and Day 1 of each subsequent 28 day cycle for nine cycles.

    Biological: RO7490677

  • Experimental
    Stage 2: Cohort 2 3mg/kg Every 4 Weeks

    Participants will be treated with single agent RO7490677 at a dose of 3.0 mg/kg IV administered as a 60 minute intravenous infusion on Days 1, 3, and 5 of Cycle 1 and Day 1 of each subsequent 28 day cycle for nine cycles.

    Biological: RO7490677

  • Experimental
    Stage 2: Cohort 3 10mg /kg Every 4 Weeks

    Participants will be treated with single agent RO7490677 at a dose of 10 mg/kg IV administered as a 60 minute intravenous infusion on Days 1, 3, and 5 of Cycle 1 and Day 1 of each subsequent 28 day cycle for nine cycles.

    Biological: RO7490677

Interventions

06

What researchers measure

Primary outcomes

  1. Stage 1 Main Phase: Overall Response Rate (ORR)

    ORR was defined as the percent of participants with a response according to the International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) criteria. This was defined as those participants who achieved clinical improvement (CI), partial remission (PR), or complete remission (CR) at a post-baseline assessment of treatment response OR had at least stable disease (SD) for three consecutive end-of-cycle response assessments (e.g. Day 1 of the subsequent cycle) in conjunction with improvement in the bone marrow fibrosis score relative to baseline by at least one grade at any time point during the period of stable disease.

    Time frame: Up until and including completion of 6 cycles. Each cycle is 28 days.

  2. Stage 2 Main Phase: Bone Marrow Response Rate (BMRR)

    Response rate was defined as the percent of participants with a reduction in bone marrow fibrosis by at least one grade according to World Health Organization (WHO) criteria from baseline to any time during the study. This was determined by a central adjudication panel of expert hematopathologists, blinded to participant, treatment, and time of biopsy.

    Time frame: Up until and including completion of 9 cycles. Each cycle is 28 days.

  3. Stage 1 Main + Open-Label Extension (OLE): ORR

    ORR was defined as the percent of participants with a response according to the IWG-MRT criteria. This was defined as those participants who achieved CI, PR, or CR at a post-baseline assessment of treatment response OR had at least SD for three consecutive end-of-cycle response assessments (e.g. Day 1 of the subsequent cycle) in conjunction with improvement in the bone marrow fibrosis score relative to baseline by at least one grade at any time point during the period of stable disease. Participants who achieved a clinical benefit in the main phase had the opportunity to remain on treatment. The determination of ORR in the main phase is outlined in the arms description below. Participants who didn't achieve a benefit had the opportunity to switch to a different dosing schedule in the OLE phase. The determination of ORR in the OLE phase is outlined in the arms descriptions below.

    Time frame: From cycle 1 day 1 up until cycle 6, day 29 (Main Phase). From cycle 7 day 1 up until study discontinuation or study termination, up to 83 cycles (OLE). Each cycle is 28 days.

  4. Stage 2 Main + Open-Label Extension (OLE): BMRR

    Defined as the percent of participants with a reduction in bone marrow fibrosis score by at least one grade according to WHO criteria at any time during the study. As determined by a central adjudication panel of expert hematopathologists, blinded to participant, treatment, and time of biopsy. Participants in the main phase had the opportunity to remain on treatment (as outlined in the arms description below). Participants also had the option to switch to the OLE phase after completing 9 cycles of the originally assigned treatment and receive PRM-151 10 mg/kg/Q4W (as outlined in the arms description below).

    Time frame: From cycle 1 day 1 up until cycle 9 day 29 (main phase). From cycle 10 day 1 up until study discontinuation or study termination, up to 51 cycles (OLE). Each cycle is 28 days.

Secondary outcomes

  1. Stage 1 Main Phase: BMRR

    Bone marrow response was defined as a reduction in bone marrow fibrosis score by at least one grade from baseline at anytime during the study.

    Time frame: Baseline, Weeks 12 and 24

  2. Stage 1 Main Phase: Modified Myeloproliferative Neoplasms Symptom Assessment Form Total Symptom Score (MPN-SAF TSS) Changes

    The MPN-SAF TSS total symptom score was the sum of the following 10 items: Filling up quickly when you eat (early satiety), abdominal discomfort, inactivity, Problems with concentration, Worst fatigue, Night sweats, Itching, Bone pain, Fever and Unintentional weight loss last 6 months. The MPN-SAF Total Symptom Score had a possible range of 0 to 100, where a lower score was more favorable. The values reported are the change from baseline scores.

    Time frame: Baseline, beginning of each cycle (Cycle 2 onward). Each cycle is 28 days.

  3. Stage 2 Main Phase: BMRR

    Response rate was defined as the percent of participants with a reduction in bone marrow fibrosis by at least one grade according to World Health Organization (WHO) criteria at any time during the study. This was determined by a central adjudication panel of expert hematopathologists, blinded to participant, treatment, and time of biopsy.

    Time frame: Up until and including completion of 9 cycles. Each cycle is 28 days.

  4. Stage 2 Main Phase: BMRR - Reduction of Bone Marrow Fibrosis by Visit

    Reduction in bone marrow fibrosis score: Reduction of at least one grade from baseline. Bone marrow fibrosis grades according to WHO criteria (as determined by central adjudication).

    Time frame: Day 1 on Cycles 4, 7, 10 and Cycle 9 Day 29. Each cycle is 28 days.

  5. Stage 2 Main Phase: Duration of Bone Marrow Improvement

    Duration of response was defined as time from first decrease from baseline \>= 1 grade to time of return to baseline levels.

    Time frame: From first decrease from baseline of one grade to time of return to baseline levels, up to cycle 9 of 28-day cycles.

  6. Stage 2 Main Phase: Hemoglobin Improvement

    Hemoglobin improvement was measured by the percent of participants with: Red cell transfusion independence (no transfusions for \>= 12 consecutive weeks) OR 50% reduction in red blood cell (RBC) transfusions for \>= 12 consecutive weeks OR percent of participants with \>= 10 g/L and \>= 20 g/L increase in hemoglobin for \>= 12 consecutive weeks without transfusions (outcome parameter assessed was dependent on baseline hemoglobin/transfusion status).

    Time frame: Up until and including completion of 9 cycles. Each cycle is 28 days.

  7. Stage 2 Main Phase: Platelet Improvement

    Platelet improvement was measured by the percent of participants with: Platelet transfusion independence (no transfusions for \>= 12 consecutive weeks) OR 50% reduction in platelets transfusions for \>= 12 consecutive weeks OR doubling of baseline platelet count for \>= 12 consecutive weeks without platelet transfusions OR platelet count \> 50 x 10e9/L for \>=12 consecutive weeks without platelet transfusions OR doubling of baseline platelet count for \>= 12 consecutive weeks without platelet transfusions OR platelet count \> 25 x 10e9/L for \>= 12 consecutive weeks without platelet transfusions (outcome parameter assessed is dependent on baseline platelet status).

    Time frame: Up until and including completion of 9 cycles. Each cycle is 28 days.

  8. Stage 2 Main Phase: Symptom Improvement

    Symptom improvement was assessed as the percent of participants with 50% reduction in MPN-SAF TSS from baseline over time. The MPN-SAF TSS total symptom score was the sum of the following 10 items: Filling up quickly when you eat (early satiety), abdominal discomfort, inactivity, Problems with concentration, Worst fatigue, Night sweats, Itching, Bone pain, Fever and Unintentional weight loss last 6 months. The MPN-SAF Total Symptom Score had a possible range of 0 to 100, where a lower score was more favorable.

    Time frame: Up until and including completion of 9 cycles. Each cycle is 28 days.

  9. Stage 2 Main Phase: Percentage of Participants With Complete Response (CR), Partial Response (PR), Clinical Improvement (CI), Stable Disease (SD), and Progressive Disease (PD) According to IWG-MRT Criteria

    Best Overall Response: (CR, PR, CI), SD and PD according to the IWG-MRT Criteria.

    Time frame: Up until and including completion of 9 cycles. Each cycle is 28 days.

Other outcomes

  1. Stage 1 Main Phase: Maximum Drug Concentration (Cmax)

    Cmax is the maximum observed RO7490677 plasma concentration.

    Time frame: Pre-dose on Cycles(C) 1, 2 and 6, Day(D) 1 and C1 D15. Each cycle is 28 days

  2. Stage 1 Main Phase: Time to Maximum Concentration (Tmax)

    Time at which the maximum plasma concentration was observed.

    Time frame: Pre-dose on Cycles(C) 1, 2 and 6, Day(D) 1 and C1 D15. Each cycle is 28 days

  3. Stage 1 Main Phase: Area Under the Curve up to the Last Measurable Concentration (AUC0-last)

    Area under the plasma concentration time curve from time 0 to time of last measurable plasma concentration.

    Time frame: Pre-dose on Cycles(C) 1, 2 and 6, Day(D) 1 and C1 D15. Each cycle is 28 days

  4. Stage 1 Main Phase: Area Under the Concentration-Time Curve Extrapolated to Infinity (AUC0-inf)

    Area under the plasma concentration-time curve from 0-time extrapolated to infinity.

    Time frame: Pre-dose on Cycles(C) 1, 2 and 6, Day(D) 1 and C1 D15. Each cycle is 28 days

  5. Stage 1 Main Phase: Terminal Elimination Half-Life (T1/2)

    Apparent terminal elimination half-life of RO7490677.

    Time frame: Pre-dose on Cycles(C) 1, 2 and 6, Day(D) 1 and C1 D15. Each cycle is 28 days

  6. Stage 1 Main Phase: Clearance (CL)

    Time frame: Pre-dose on Cycles(C) 1, 2 and 6, Day(D) 1 and C1 D15. Each cycle is 28 days

  7. Stage 1 Main Phase: Volume of Distribution (Vd)

    Time frame: Pre-dose on Cycles(C) 1, 2 and 6, Day(D) 1 and C1 D15. Each cycle is 28 days

  8. Percentage of Participants With Adverse Events (AEs) and Infusion Related Reactions (IRRs)

    An AE was defined as any noxious, pathologic, or unintended change in anatomical, physiologic, or metabolic function as indicated by physical signs, symptoms, or laboratory changes occurring in any phase of a clinical study, whether or not considered investigational product-related. Pre-existing conditions which worsened during the study were also considered as adverse events. IRRs were considerd to be Adverse Events of Special Interest (AESI). Grading was completed according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), version 4.0.

    Time frame: Baseline up until 6.75 years

  9. Percentage of Participants With Serious Adverse Events (SAEs) and AEs Leading to Study Drug Discontinuation

    An SAE was defined as any AE that occurred at any dose the resulted in death; was life-threatening; required hospitalization or prolongation of existing hospitalizations; a persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions; a congenital anomaly or birth defect. An AE was defined as any noxious, pathologic, or unintended change in anatomical, physiologic, or metabolic function as indicated by physical signs, symptoms, or laboratory changes occurring in any phase of a clinical study, whether or not considered investigational product-related. Pre-existing conditions which worsened during the study were also considered as adverse events. Grading was completed according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), version 4.0.

    Time frame: Baseline up until 6.75 years

07

Results

Posted Jan 5, 2022

Participant flow

A total of 125 participants were enrolled at sites in 8 different countries.

Main Phase Stage 1
Participant flow — Main Phase Stage 1
MilestoneMain Phase Stage 1: RO7490677 10 mg/kg IV Every Week (QW)Main Phase Stage 1: RO7490677 10 mg/kg IV Every 4 Weeks (Q4W)Main Phase Stage 1: RO7490677 10 mg/kg IV QW + RuxolitinibMain Phase Stage 1: RO7490677 10 mg/kg IV Q4W+ RuxolitinibMain Phase Stage 2: RO7490677 0.3 mg/kg IV Q4WMain Phase Stage 2: RO7490677 3 mg/kg IV Q4WMain Phase Stage 2: RO7490677 10 mg/kg IV Q4WOLE Stage 1: RO7490677 10 mg/kg IV Q4WOLE Stage 1: RO7490677 10 mg/kg IV Q4W + RuxolitinibOLE Stage 2: RO7490677 10 mg/kg IV Q4W
Started8766000000
Completed5546000000
Not completed3220000000
Withdrew: Death2000000000
Withdrew: Informed consent withdrawn1000000000
Withdrew: Lack of efficacy0200000000
Withdrew: Various reasons0020000000
Main Phase Stage 2
Participant flow — Main Phase Stage 2
MilestoneMain Phase Stage 1: RO7490677 10 mg/kg IV Every Week (QW)Main Phase Stage 1: RO7490677 10 mg/kg IV Every 4 Weeks (Q4W)Main Phase Stage 1: RO7490677 10 mg/kg IV QW + RuxolitinibMain Phase Stage 1: RO7490677 10 mg/kg IV Q4W+ RuxolitinibMain Phase Stage 2: RO7490677 0.3 mg/kg IV Q4WMain Phase Stage 2: RO7490677 3 mg/kg IV Q4WMain Phase Stage 2: RO7490677 10 mg/kg IV Q4WOLE Stage 1: RO7490677 10 mg/kg IV Q4WOLE Stage 1: RO7490677 10 mg/kg IV Q4W + RuxolitinibOLE Stage 2: RO7490677 10 mg/kg IV Q4W
Started0000333232000
Completed0000201615000
Not completed0000131617000
Withdrew: Adverse event0000657000
Withdrew: Informed consent withdrawn0000433000
Withdrew: Lack of efficacy0000120000
Withdrew: Various reasons0000201000
Withdrew: Progressive disease0000066000
Open Label Extension (OLE)
Participant flow — Open Label Extension (OLE)
MilestoneMain Phase Stage 1: RO7490677 10 mg/kg IV Every Week (QW)Main Phase Stage 1: RO7490677 10 mg/kg IV Every 4 Weeks (Q4W)Main Phase Stage 1: RO7490677 10 mg/kg IV QW + RuxolitinibMain Phase Stage 1: RO7490677 10 mg/kg IV Q4W+ RuxolitinibMain Phase Stage 2: RO7490677 0.3 mg/kg IV Q4WMain Phase Stage 2: RO7490677 3 mg/kg IV Q4WMain Phase Stage 2: RO7490677 10 mg/kg IV Q4WOLE Stage 1: RO7490677 10 mg/kg IV Q4WOLE Stage 1: RO7490677 10 mg/kg IV Q4W + RuxolitinibOLE Stage 2: RO7490677 10 mg/kg IV Q4W
Started000000013548
Completed0000000100
Not completed000000012548
Withdrew: Adverse event0000000218
Withdrew: Lack of efficacy00000004119
Withdrew: Various reasons0000000313
Withdrew: Progressive disease0000000329
Withdrew: Informed consent withdrawn0000000008
Withdrew: Lost to follow-up0000000001

Outcome measures

PrimaryStage 1 Main Phase: Overall Response Rate (ORR)

ORR was defined as the percent of participants with a response according to the International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) criteria. This was defined as those participants who achieved clinical improvement (CI), partial remission (PR), or complete remission (CR) at a post-baseline assessment of treatment response OR had at least stable disease (SD) for three consecutive end-of-cycle response assessments (e.g. Day 1 of the subsequent cycle) in conjunction with improvement in the bone marrow fibrosis score relative to baseline by at least one grade at any time point during the period of stable disease.

Time frame:
Up until and including completion of 6 cycles. Each cycle is 28 days.
Reported as:
Number · Percentage of Participants
Stage 1 Main Phase: Overall Response Rate (ORR)
Percentage of ParticipantsMain Phase Stage 1: RO7490677 10 mg/kg IV Every Week (QW)Main Phase Stage 1: RO7490677 10 mg/kg IV Every 4 Weeks (Q4W)Main Phase Stage 1: RO7490677 10 mg/kg IV QW + RuxolitinibMain Phase Stage 1: RO7490677 10 mg/kg IV Q4W+ Ruxolitinib
Stage 1 Main Phase: Overall Response Rate (ORR)37.5 (11.11 to 71.08)14.3 (0.73 to 52.07)33.3 (6.28 to 72.87)50.0 (15.32 to 84.68)
PrimaryStage 2 Main Phase: Bone Marrow Response Rate (BMRR)

Response rate was defined as the percent of participants with a reduction in bone marrow fibrosis by at least one grade according to World Health Organization (WHO) criteria from baseline to any time during the study. This was determined by a central adjudication panel of expert hematopathologists, blinded to participant, treatment, and time of biopsy.

Time frame:
Up until and including completion of 9 cycles. Each cycle is 28 days.
Reported as:
Number · Percentage of Participants
Stage 2 Main Phase: Bone Marrow Response Rate (BMRR)
Percentage of ParticipantsMain Phase Stage 2: RO7490677 0.3 mg/kg IV Q4WMain Phase Stage 2: RO7490677 3 mg/kg IV Q4WMain Phase Stage 2: RO7490677 10 mg/kg IV Q4W
Stage 2 Main Phase: Bone Marrow Response Rate (BMRR)30.3 (14.62 to 45.98)31.3 (15.19 to 47.31)25.0 (10.00 to 40.00)
PrimaryStage 1 Main + Open-Label Extension (OLE): ORR

ORR was defined as the percent of participants with a response according to the IWG-MRT criteria. This was defined as those participants who achieved CI, PR, or CR at a post-baseline assessment of treatment response OR had at least SD for three consecutive end-of-cycle response assessments (e.g. Day 1 of the subsequent cycle) in conjunction with improvement in the bone marrow fibrosis score relative to baseline by at least one grade at any time point during the period of stable disease. Participants who achieved a clinical benefit in the main phase had the opportunity to remain on treatment. The determination of ORR in the main phase is outlined in the arms description below. Participants who didn't achieve a benefit had the opportunity to switch to a different dosing schedule in the OLE phase. The determination of ORR in the OLE phase is outlined in the arms descriptions below.

Time frame:
From cycle 1 day 1 up until cycle 6, day 29 (Main Phase). From cycle 7 day 1 up until study discontinuation or study termination, up to 83 cycles (OLE). Each cycle is 28 days.
Reported as:
Number · Percentage of Participants
Stage 1 Main + Open-Label Extension (OLE): ORR
Percentage of ParticipantsMain Phase Stage 1: RO7490677 10 mg/kg IV QW; OLE: RO7490677 10 mg/kg IV Q4WMain Phase Stage 1: RO7490677 10 mg/kg IV Q4W; OLE: RO7490677 10 mg/kg IV Q4WMain Phase Stage 1: RO7490677 10 mg/kg IV QW + Ruxolitinib; OLE: RO7490677 10 mg/kg IV Q4W + Ruxo.Main Phase Stage 1: RO7490677 10 mg/kg IV Q4W + Ruxolitinib; OLE: RO7490677 10 mg/kg IV Q4W + Ruxo.
Stage 1 Main + Open-Label Extension (OLE): ORR50.0 (19.29 to 80.71)71.4 (34.13 to 94.66)50.0 (15.32 to 84.68)66.7 (27.13 to 93.72)
PrimaryStage 2 Main + Open-Label Extension (OLE): BMRR

Defined as the percent of participants with a reduction in bone marrow fibrosis score by at least one grade according to WHO criteria at any time during the study. As determined by a central adjudication panel of expert hematopathologists, blinded to participant, treatment, and time of biopsy. Participants in the main phase had the opportunity to remain on treatment (as outlined in the arms description below). Participants also had the option to switch to the OLE phase after completing 9 cycles of the originally assigned treatment and receive PRM-151 10 mg/kg/Q4W (as outlined in the arms description below).

Time frame:
From cycle 1 day 1 up until cycle 9 day 29 (main phase). From cycle 10 day 1 up until study discontinuation or study termination, up to 51 cycles (OLE). Each cycle is 28 days.
Reported as:
Number · Percentage of Participants
Stage 2 Main + Open-Label Extension (OLE): BMRR
Percentage of ParticipantsMain Phase Stage 2: RO7490677 0.3 mg/kg IV Q4W; OLE: RO7490677 10 mg/kg IV Q4WMain Phase Stage 2: RO7490677 3 mg/kg IV Q4W; OLE: RO7490677 10 mg/kg IV Q4WMain Phase Stage 2: RO7490677 10 mg/kg IV Q4W; OLE: RO7490677 10 mg/kg IV Q4W
Stage 2 Main + Open-Label Extension (OLE): BMRR30.3 (14.62 to 45.98)34.4 (17.92 to 50.83)25.0 (10.00 to 40.00)
SecondaryStage 1 Main Phase: BMRR

Bone marrow response was defined as a reduction in bone marrow fibrosis score by at least one grade from baseline at anytime during the study.

Time frame:
Baseline, Weeks 12 and 24
Reported as:
Number · Percentage of Participants
Stage 1 Main Phase: BMRR
Percentage of ParticipantsMain Phase Stage 1: RO7490677 10 mg/kg IV Every Week (QW)Main Phase Stage 1: RO7490677 10 mg/kg IV Every 4 Weeks (Q4W)Main Phase Stage 1: RO7490677 10 mg/kg IV QW + RuxolitinibMain Phase Stage 1: RO7490677 10 mg/kg IV Q4W+ Ruxolitinib
Stage 1 Main Phase: BMRR37.5 (3.95 to 71.05)14.3 (0.00 to 40.21)16.7 (0.00 to 46.49)50.0 (9.99 to 90.01)
SecondaryStage 1 Main Phase: Modified Myeloproliferative Neoplasms Symptom Assessment Form Total Symptom Score (MPN-SAF TSS) Changes

The MPN-SAF TSS total symptom score was the sum of the following 10 items: Filling up quickly when you eat (early satiety), abdominal discomfort, inactivity, Problems with concentration, Worst fatigue, Night sweats, Itching, Bone pain, Fever and Unintentional weight loss last 6 months. The MPN-SAF Total Symptom Score had a possible range of 0 to 100, where a lower score was more favorable. The values reported are the change from baseline scores.

Time frame:
Baseline, beginning of each cycle (Cycle 2 onward). Each cycle is 28 days.
Reported as:
Mean · Score on a scale
Stage 1 Main Phase: Modified Myeloproliferative Neoplasms Symptom Assessment Form Total Symptom Score (MPN-SAF TSS) Changes
Score on a scaleMain Phase Stage 1: RO7490677 10 mg/kg IV Every Week (QW)Main Phase Stage 1: RO7490677 10 mg/kg IV Every 4 Weeks (Q4W)Main Phase Stage 1: RO7490677 10 mg/kg IV QW + RuxolitinibMain Phase Stage 1: RO7490677 10 mg/kg IV Q4W+ Ruxolitinib
Baseline23.1 ± 19.116.9 ± 7.226.8 ± 17.115.3 ± 10.4
Cycle(C)2 Day(D)1-5.3 ± 12.65.7 ± 11.80.5 ± 8.8-2.0 ± 5.0
C3D1-9.1 ± 10.91.9 ± 5.3-2.7 ± 14.84.2 ± 8.0
C4D1-8.7 ± 10.71.0 ± 8.0-7.5 ± 6.05.7 ± 20.9
C5D1-13.2 ± 13.22.6 ± 6.9-6.7 ± 10.61.5 ± 13.6
C6D1-12.2 ± 9.5-0.8 ± 8.3-5.4 ± 6.24.3 ± 11.5
C6D29-15.0 ± 13.7-2.2 ± 5.3-5.3 ± 4.62.3 ± 8.8
SecondaryStage 2 Main Phase: BMRR

Response rate was defined as the percent of participants with a reduction in bone marrow fibrosis by at least one grade according to World Health Organization (WHO) criteria at any time during the study. This was determined by a central adjudication panel of expert hematopathologists, blinded to participant, treatment, and time of biopsy.

Time frame:
Up until and including completion of 9 cycles. Each cycle is 28 days.
Reported as:
Number · Percentage of Participants
Stage 2 Main Phase: BMRR
Percentage of ParticipantsMain Phase Stage 2: RO7490677 0.3 mg/kg IV Q4WMain Phase Stage 2: RO7490677 3 mg/kg IV Q4WMain Phase Stage 2: RO7490677 10 mg/kg IV Q4W
Stage 2 Main Phase: BMRR30.3 (14.62 to 45.98)31.3 (15.19 to 47.31)25.0 (10.0 to 40.00)
SecondaryStage 2 Main Phase: BMRR - Reduction of Bone Marrow Fibrosis by Visit

Reduction in bone marrow fibrosis score: Reduction of at least one grade from baseline. Bone marrow fibrosis grades according to WHO criteria (as determined by central adjudication).

Time frame:
Day 1 on Cycles 4, 7, 10 and Cycle 9 Day 29. Each cycle is 28 days.
Reported as:
Number · Percentage of Participants
Stage 2 Main Phase: BMRR - Reduction of Bone Marrow Fibrosis by Visit
Percentage of ParticipantsMain Phase Stage 2: RO7490677 0.3 mg/kg IV Q4WMain Phase Stage 2: RO7490677 3 mg/kg IV Q4WMain Phase Stage 2: RO7490677 10 mg/kg IV Q4W
Cycle(C) 4 Day(D) 110.724.019.2
C7D123.811.810.5
C9D29/C10D130.021.413.3
SecondaryStage 2 Main Phase: Duration of Bone Marrow Improvement

Duration of response was defined as time from first decrease from baseline \>= 1 grade to time of return to baseline levels.

Time frame:
From first decrease from baseline of one grade to time of return to baseline levels, up to cycle 9 of 28-day cycles.
Reported as:
Median · Weeks
Stage 2 Main Phase: Duration of Bone Marrow Improvement
WeeksMain Phase Stage 2: RO7490677 0.3 mg/kg IV Q4WMain Phase Stage 2: RO7490677 3 mg/kg IV Q4WMain Phase Stage 2: RO7490677 10 mg/kg IV Q4W
Stage 2 Main Phase: Duration of Bone Marrow ImprovementNA (12.0 to NA)12.0 (12.0 to NA)12.1 (11.4 to 13.0)
SecondaryStage 2 Main Phase: Hemoglobin Improvement

Hemoglobin improvement was measured by the percent of participants with: Red cell transfusion independence (no transfusions for \>= 12 consecutive weeks) OR 50% reduction in red blood cell (RBC) transfusions for \>= 12 consecutive weeks OR percent of participants with \>= 10 g/L and \>= 20 g/L increase in hemoglobin for \>= 12 consecutive weeks without transfusions (outcome parameter assessed was dependent on baseline hemoglobin/transfusion status).

Time frame:
Up until and including completion of 9 cycles. Each cycle is 28 days.
Reported as:
Number · Percentage of Participants
Stage 2 Main Phase: Hemoglobin Improvement
Percentage of ParticipantsMain Phase Stage 2: RO7490677 0.3 mg/kg IV Q4WMain Phase Stage 2: RO7490677 3 mg/kg IV Q4WMain Phase Stage 2: RO7490677 10 mg/kg IV Q4W
Stage 2 Main Phase: Hemoglobin Improvement15.215.66.3
SecondaryStage 2 Main Phase: Platelet Improvement

Platelet improvement was measured by the percent of participants with: Platelet transfusion independence (no transfusions for \>= 12 consecutive weeks) OR 50% reduction in platelets transfusions for \>= 12 consecutive weeks OR doubling of baseline platelet count for \>= 12 consecutive weeks without platelet transfusions OR platelet count \> 50 x 10e9/L for \>=12 consecutive weeks without platelet transfusions OR doubling of baseline platelet count for \>= 12 consecutive weeks without platelet transfusions OR platelet count \> 25 x 10e9/L for \>= 12 consecutive weeks without platelet transfusions (outcome parameter assessed is dependent on baseline platelet status).

Time frame:
Up until and including completion of 9 cycles. Each cycle is 28 days.
Reported as:
Number · Percentage of Participants
Stage 2 Main Phase: Platelet Improvement
Percentage of ParticipantsMain Phase Stage 2: RO7490677 0.3 mg/kg IV Q4WMain Phase Stage 2: RO7490677 3 mg/kg IV Q4WMain Phase Stage 2: RO7490677 10 mg/kg IV Q4W
Stage 2 Main Phase: Platelet Improvement27.334.437.5
SecondaryStage 2 Main Phase: Symptom Improvement

Symptom improvement was assessed as the percent of participants with 50% reduction in MPN-SAF TSS from baseline over time. The MPN-SAF TSS total symptom score was the sum of the following 10 items: Filling up quickly when you eat (early satiety), abdominal discomfort, inactivity, Problems with concentration, Worst fatigue, Night sweats, Itching, Bone pain, Fever and Unintentional weight loss last 6 months. The MPN-SAF Total Symptom Score had a possible range of 0 to 100, where a lower score was more favorable.

Time frame:
Up until and including completion of 9 cycles. Each cycle is 28 days.
Reported as:
Count of participants · Participants
Stage 2 Main Phase: Symptom Improvement
ParticipantsMain Phase Stage 2: RO7490677 0.3 mg/kg IV Q4WMain Phase Stage 2: RO7490677 3 mg/kg IV Q4WMain Phase Stage 2: RO7490677 10 mg/kg IV Q4W
Cycle(C) 2 Day(D) 1521
C3D1632
C4D1342
C5D1521
C6D1833
C7D1850
C8D1530
C9D1531
C9D29/C10D1520
SecondaryStage 2 Main Phase: Percentage of Participants With Complete Response (CR), Partial Response (PR), Clinical Improvement (CI), Stable Disease (SD), and Progressive Disease (PD) According to IWG-MRT Criteria

Best Overall Response: (CR, PR, CI), SD and PD according to the IWG-MRT Criteria.

Time frame:
Up until and including completion of 9 cycles. Each cycle is 28 days.
Reported as:
Count of participants · Participants
Stage 2 Main Phase: Percentage of Participants With Complete Response (CR), Partial Response (PR), Clinical Improvement (CI), Stable Disease (SD), and Progressive Disease (PD) According to IWG-MRT Criteria
ParticipantsMain Phase Stage 2: RO7490677 0.3 mg/kg IV Q4WMain Phase Stage 2: RO7490677 3 mg/kg IV Q4WMain Phase Stage 2: RO7490677 10 mg/kg IV Q4W
CR000
PR000
CI862
SD202126
PD334
Not evaluable220
Other pre-specifiedStage 1 Main Phase: Maximum Drug Concentration (Cmax)

Cmax is the maximum observed RO7490677 plasma concentration.

Time frame:
Pre-dose on Cycles(C) 1, 2 and 6, Day(D) 1 and C1 D15. Each cycle is 28 days
Reported as:
Geometric mean · Micrograms per Milliliter (ug/mL)
Stage 1 Main Phase: Maximum Drug Concentration (Cmax)
Micrograms per Milliliter (ug/mL)Main Phase Stage 1: RO7490677 10 mg/kg IV Every Week (QW)Main Phase Stage 1: RO7490677 10 mg/kg IV Every 4 Weeks (Q4W)Main Phase Stage 1: RO7490677 10 mg/kg IV QW + RuxolitinibMain Phase Stage 1: RO7490677 10 mg/kg IV Q4W+ Ruxolitinib
C1D1133 ± 48.4113 ± 28.1164 ± 23.9112 ± 90.4
C1D15127 ± 31.9—126 ± 27.5—
C2D1107 ± 26.9110 ± 20.9149 ± 29.1130 ± 80.2
C6D1142 ± 70.0111 ± 28.0136 ± 34.1142 ± 27.4
Other pre-specifiedStage 1 Main Phase: Time to Maximum Concentration (Tmax)

Time at which the maximum plasma concentration was observed.

Time frame:
Pre-dose on Cycles(C) 1, 2 and 6, Day(D) 1 and C1 D15. Each cycle is 28 days
Reported as:
Median · Hour (hr)
Stage 1 Main Phase: Time to Maximum Concentration (Tmax)
Hour (hr)Main Phase Stage 1: RO7490677 10 mg/kg IV Every Week (QW)Main Phase Stage 1: RO7490677 10 mg/kg IV Every 4 Weeks (Q4W)Main Phase Stage 1: RO7490677 10 mg/kg IV QW + RuxolitinibMain Phase Stage 1: RO7490677 10 mg/kg IV Q4W+ Ruxolitinib
C1D11.12 (1.00 to 2.00)1.10 (1.00 to 2.08)1.14 (1.00 to 2.25)1.13 (1.00 to 5.00)
C1D151.13 (1.03 to 1.80)—1.65 (1.02 to 2.50)—
C2D11.10 (1.00 to 3.17)1.08 (1.03 to 1.08)1.05 (1.00 to 1.32)1.44 (1.00 to 9.00)
C6D12.00 (1.03 to 5.20)1.07 (1.00 to 2.03)1.17 (1.05 to 5.00)1.01 (1.00 to 1.08)
Other pre-specifiedStage 1 Main Phase: Area Under the Curve up to the Last Measurable Concentration (AUC0-last)

Area under the plasma concentration time curve from time 0 to time of last measurable plasma concentration.

Time frame:
Pre-dose on Cycles(C) 1, 2 and 6, Day(D) 1 and C1 D15. Each cycle is 28 days
Reported as:
Geometric mean · ug*hour/mL
Stage 1 Main Phase: Area Under the Curve up to the Last Measurable Concentration (AUC0-last)
ug*hour/mLMain Phase Stage 1: RO7490677 10 mg/kg IV Every Week (QW)Main Phase Stage 1: RO7490677 10 mg/kg IV Every 4 Weeks (Q4W)Main Phase Stage 1: RO7490677 10 mg/kg IV QW + RuxolitinibMain Phase Stage 1: RO7490677 10 mg/kg IV Q4W+ Ruxolitinib
C1D11810 ± 72.01690 ± 26.12590 ± 28.71500 ± 158.3
C1D151460 ± 142.0—2590 ± 187.6—
C2D1127.3 ± 904504 ± 84.72990 ± 92.0663 ± 79.5
C6D1698 ± 63.0570 ± 44.8764 ± 28.9703 ± 33.8
Other pre-specifiedStage 1 Main Phase: Area Under the Concentration-Time Curve Extrapolated to Infinity (AUC0-inf)

Area under the plasma concentration-time curve from 0-time extrapolated to infinity.

Time frame:
Pre-dose on Cycles(C) 1, 2 and 6, Day(D) 1 and C1 D15. Each cycle is 28 days
Reported as:
Geometric mean · ug*hour/mL
Stage 1 Main Phase: Area Under the Concentration-Time Curve Extrapolated to Infinity (AUC0-inf)
ug*hour/mLMain Phase Stage 1: RO7490677 10 mg/kg IV Every Week (QW)Main Phase Stage 1: RO7490677 10 mg/kg IV Every 4 Weeks (Q4W)Main Phase Stage 1: RO7490677 10 mg/kg IV QW + RuxolitinibMain Phase Stage 1: RO7490677 10 mg/kg IV Q4W+ Ruxolitinib
C1D12830 ± 12.92050 ± 29.52970 ± 34.93130 ± 8.6
C1D153450 ± 2.8—6060 ± 23.2—
C2D12170 ± 170.9—4230 ± 34.8—
C6D1——819 ± NA—
Other pre-specifiedStage 1 Main Phase: Terminal Elimination Half-Life (T1/2)

Apparent terminal elimination half-life of RO7490677.

Time frame:
Pre-dose on Cycles(C) 1, 2 and 6, Day(D) 1 and C1 D15. Each cycle is 28 days
Reported as:
Geometric mean · hr
Stage 1 Main Phase: Terminal Elimination Half-Life (T1/2)
hrMain Phase Stage 1: RO7490677 10 mg/kg IV Every Week (QW)Main Phase Stage 1: RO7490677 10 mg/kg IV Every 4 Weeks (Q4W)Main Phase Stage 1: RO7490677 10 mg/kg IV QW + RuxolitinibMain Phase Stage 1: RO7490677 10 mg/kg IV Q4W+ Ruxolitinib
C1D114.7 ± 19.217.2 ± 23.716.8 ± 17.718.4 ± 7.9
C1D1531.2 ± 45.0—40.4 ± 12.6—
C2D118.0 ± 220.6—30.0 ± 48.6—
C6D1——1.95 ± NA—
Other pre-specifiedStage 1 Main Phase: Clearance (CL)
Time frame:
Pre-dose on Cycles(C) 1, 2 and 6, Day(D) 1 and C1 D15. Each cycle is 28 days
Reported as:
Geometric mean · Litres per hour (L/hr)
Stage 1 Main Phase: Clearance (CL)
Litres per hour (L/hr)Main Phase Stage 1: RO7490677 10 mg/kg IV Every Week (QW)Main Phase Stage 1: RO7490677 10 mg/kg IV Every 4 Weeks (Q4W)Main Phase Stage 1: RO7490677 10 mg/kg IV QW + RuxolitinibMain Phase Stage 1: RO7490677 10 mg/kg IV Q4W+ Ruxolitinib
C1D10.258 ± 9.00.362 ± 31.50.269 ± 32.90.233 ± 33.3
C1D150.233 ± 24.9—0.147 ± 35.0—
C2D10.382 ± 229.9—0.189 ± 55.5—
C6D1——1.42 ± NA—
Other pre-specifiedStage 1 Main Phase: Volume of Distribution (Vd)
Time frame:
Pre-dose on Cycles(C) 1, 2 and 6, Day(D) 1 and C1 D15. Each cycle is 28 days
Reported as:
Geometric mean · Litres (L)
Stage 1 Main Phase: Volume of Distribution (Vd)
Litres (L)Main Phase Stage 1: RO7490677 10 mg/kg IV Every Week (QW)Main Phase Stage 1: RO7490677 10 mg/kg IV Every 4 Weeks (Q4W)Main Phase Stage 1: RO7490677 10 mg/kg IV QW + RuxolitinibMain Phase Stage 1: RO7490677 10 mg/kg IV Q4W+ Ruxolitinib
C1D15.47 ± 10.99.00 ± 28.86.52 ± 26.46.17 ± 38.9
C1D1510.5 ± 62.4—8.57 ± 47.6—
C2D19.93 ± 63.0—8.18 ± 24.5—
C6D1——4.01 ± NA—
Other pre-specifiedPercentage of Participants With Adverse Events (AEs) and Infusion Related Reactions (IRRs)

An AE was defined as any noxious, pathologic, or unintended change in anatomical, physiologic, or metabolic function as indicated by physical signs, symptoms, or laboratory changes occurring in any phase of a clinical study, whether or not considered investigational product-related. Pre-existing conditions which worsened during the study were also considered as adverse events. IRRs were considerd to be Adverse Events of Special Interest (AESI). Grading was completed according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), version 4.0.

Time frame:
Baseline up until 6.75 years
Reported as:
Number · Percentage of Participants
Percentage of Participants With Adverse Events (AEs) and Infusion Related Reactions (IRRs)
Percentage of ParticipantsMain Phase Stage 1: RO7490677 10 mg/kg IV Every Week (QW)Main Phase Stage 1: RO7490677 10 mg/kg IV Every 4 Weeks (Q4W)Main Phase Stage 1: RO7490677 10 mg/kg IV QW + RuxolitinibMain Phase Stage 1: RO7490677 10 mg/kg IV Q4W+ RuxolitinibMain Phase Stage 2: RO7490677 0.3 mg/kg IV Q4WMain Phase Stage 2: RO7490677 3 mg/kg IV Q4WMain Phase Stage 2: RO7490677 10 mg/kg IV Q4WOLE Stage 1: RO7490677 10 mg/kg IV Every 4 Weeks (Q4W)OLE Stage 1: RO7490677 10 mg/kg IV Q4W+ RuxolitinibOLE Stage 2: RO7490677 10 mg/kg IV Q4W
AEs10085.710010010010010092.310089.6
IRRs00016.73.03.16.37.720.02.1
Other pre-specifiedPercentage of Participants With Serious Adverse Events (SAEs) and AEs Leading to Study Drug Discontinuation

An SAE was defined as any AE that occurred at any dose the resulted in death; was life-threatening; required hospitalization or prolongation of existing hospitalizations; a persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions; a congenital anomaly or birth defect. An AE was defined as any noxious, pathologic, or unintended change in anatomical, physiologic, or metabolic function as indicated by physical signs, symptoms, or laboratory changes occurring in any phase of a clinical study, whether or not considered investigational product-related. Pre-existing conditions which worsened during the study were also considered as adverse events. Grading was completed according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), version 4.0.

Time frame:
Baseline up until 6.75 years
Reported as:
Number · Percentage of Participants
Percentage of Participants With Serious Adverse Events (SAEs) and AEs Leading to Study Drug Discontinuation
Percentage of ParticipantsMain Phase Stage 1: RO7490677 10 mg/kg IV Every Week (QW)Main Phase Stage 1: RO7490677 10 mg/kg IV Every 4 Weeks (Q4W)Main Phase Stage 1: RO7490677 10 mg/kg IV QW + RuxolitinibMain Phase Stage 1: RO7490677 10 mg/kg IV Q4W+ RuxolitinibMain Phase Stage 2: RO7490677 0.3 mg/kg IV Q4WMain Phase Stage 2: RO7490677 3 mg/kg IV Q4WMain Phase Stage 2: RO7490677 10 mg/kg IV Q4WOLE Stage 1: RO7490677 10 mg/kg IV Every 4 Weeks (Q4W)OLE Stage 1: RO7490677 10 mg/kg IV Q4W+ RuxolitinibOLE Stage 2: RO7490677 10 mg/kg IV Q4W
SAEs25.000015.215.628.17.7022.9
AEs25.000021.234.437.530.8027.1

Adverse events

Collected over Baseline up until 6.75 years. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Main Phase Stage 1: RO7490677 10 mg/kg IV Every Week (QW)2/8 (25%)2/8 (25%)8/8 (100%)
Main Phase Stage 1: RO7490677 10 mg/kg IV Every 4 Weeks (Q4W)0/7 (0%)1/7 (14.3%)6/7 (85.7%)
Main Phase Stage 1: RO7490677 10 mg/kg IV QW + Ruxolitinib1/6 (16.7%)2/6 (33.3%)6/6 (100%)
Main Phase Stage 1: RO7490677 10 mg/kg IV Q4W+ Ruxolitinib0/6 (0%)0/6 (0%)6/6 (100%)
Main Phase Stage 2: RO7490677 0.3 mg/kg IV Q4W7/33 (21.2%)11/33 (33.3%)32/33 (97%)
Main Phase Stage 2: RO7490677 3 mg/kg IV Q4W6/32 (18.8%)14/32 (43.8%)30/32 (93.8%)
Main Phase Stage 2: RO7490677 10 mg/kg IV Q4W9/32 (28.1%)14/32 (43.8%)31/32 (96.9%)
OLE Stage 1: RO7490677 10 mg/kg IV Q4W0/13 (0%)5/13 (38.5%)12/13 (92.3%)
OLE Stage 1: RO7490677 10 mg/kg IV Q4W + Ruxolitinib0/5 (0%)2/5 (40%)5/5 (100%)
OLE Stage 2: RO7490677 10 mg/kg IV Q4W7/48 (14.6%)22/48 (45.8%)32/48 (66.7%)
Most frequent serious events
Showing 10 of 102
Most frequent serious events
EventMain Phase Stage 1: RO7490677 10 mg/kg IV Every Week (QW)Main Phase Stage 1: RO7490677 10 mg/kg IV Every 4 Weeks (Q4W)Main Phase Stage 1: RO7490677 10 mg/kg IV QW + RuxolitinibMain Phase Stage 1: RO7490677 10 mg/kg IV Q4W+ RuxolitinibMain Phase Stage 2: RO7490677 0.3 mg/kg IV Q4WMain Phase Stage 2: RO7490677 3 mg/kg IV Q4WMain Phase Stage 2: RO7490677 10 mg/kg IV Q4WOLE Stage 1: RO7490677 10 mg/kg IV Q4WOLE Stage 1: RO7490677 10 mg/kg IV Q4W + RuxolitinibOLE Stage 2: RO7490677 10 mg/kg IV Q4W
InfectionInfections and infestations0/80/70/60/60/330/320/320/131/51/48
PneumoniaInfections and infestations0/80/71/60/62/331/322/320/131/53/48
Upper gastrointestinal haemorrhageGastrointestinal disorders0/80/70/60/60/330/320/320/131/50/48
Enterocolitis infectiousInfections and infestations0/80/70/60/60/330/320/320/131/50/48
Wound infectionInfections and infestations0/80/70/60/60/330/320/321/131/50/48
Squamous cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/80/70/60/60/330/320/320/131/50/48
Respiratory syncytial virus infectionInfections and infestations0/80/71/60/60/330/320/320/130/50/48
SialoadenitisInfections and infestations0/80/71/60/60/330/320/320/130/50/48
Abdominal painGastrointestinal disorders0/81/70/60/60/330/321/320/130/50/48
Cardiac arrestCardiac disorders1/80/70/60/60/330/320/320/130/50/48
Most frequent other events
Showing 10 of 179
Most frequent other events
EventMain Phase Stage 1: RO7490677 10 mg/kg IV Every Week (QW)Main Phase Stage 1: RO7490677 10 mg/kg IV Every 4 Weeks (Q4W)Main Phase Stage 1: RO7490677 10 mg/kg IV QW + RuxolitinibMain Phase Stage 1: RO7490677 10 mg/kg IV Q4W+ RuxolitinibMain Phase Stage 2: RO7490677 0.3 mg/kg IV Q4WMain Phase Stage 2: RO7490677 3 mg/kg IV Q4WMain Phase Stage 2: RO7490677 10 mg/kg IV Q4WOLE Stage 1: RO7490677 10 mg/kg IV Q4WOLE Stage 1: RO7490677 10 mg/kg IV Q4W + RuxolitinibOLE Stage 2: RO7490677 10 mg/kg IV Q4W
ArthralgiaMusculoskeletal and connective tissue disorders0/80/71/61/63/335/322/322/134/53/48
Squamous cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/80/70/60/62/330/320/320/133/50/48
CoughRespiratory, thoracic and mediastinal disorders1/80/72/61/610/337/325/322/133/54/48
PyrexiaGeneral disorders0/80/70/63/64/337/323/320/131/52/48
NauseaGastrointestinal disorders2/81/71/60/62/332/325/324/132/53/48
VomitingGastrointestinal disorders0/81/71/60/61/332/325/322/132/50/48
BronchitisInfections and infestations0/80/70/60/63/330/321/320/132/50/48
Alanine aminotransferase increasedInvestigations3/80/70/60/62/334/321/320/132/50/48
Aspartate aminotransferase increasedInvestigations0/80/70/60/61/335/321/320/132/50/48
HeadacheNervous system disorders0/80/72/61/64/337/323/322/132/53/48

Baseline characteristics

Stage 1 \& Stage 2 reported separately.

Age, Continuous
Age, Continuous(Years)Main Phase Stage 1: RO7490677 10 mg/kg IV Every Week (QW)Main Phase Stage 1: RO7490677 10 mg/kg IV Every 4 Weeks (Q4W)Main Phase Stage 1: RO7490677 10 mg/kg IV QW + RuxolitinibMain Phase Stage 1: RO7490677 10 mg/kg IV Q4W+ RuxolitinibMain Phase Stage 2: RO7490677 0.3 mg/kg IV Q4WMain Phase Stage 2: RO7490677 3 mg/kg IV Q4WMain Phase Stage 2: RO7490677 10 mg/kg IV Q4WTotal
Mean64.3 ± 11.470.7 ± 6.366.0 ± 7.366.2 ± 8.6———66.7 ± 8.7
Age, Continuous
Age, Continuous(Years)Main Phase Stage 1: RO7490677 10 mg/kg IV Every Week (QW)Main Phase Stage 1: RO7490677 10 mg/kg IV Every 4 Weeks (Q4W)Main Phase Stage 1: RO7490677 10 mg/kg IV QW + RuxolitinibMain Phase Stage 1: RO7490677 10 mg/kg IV Q4W+ RuxolitinibMain Phase Stage 2: RO7490677 0.3 mg/kg IV Q4WMain Phase Stage 2: RO7490677 3 mg/kg IV Q4WMain Phase Stage 2: RO7490677 10 mg/kg IV Q4WTotal
Mean————70.6 ± 7.170.2 ± 6.569.4 ± 8.970.1 ± 7.5
Sex: Female, Male
Sex: Female, Male(Participants)Main Phase Stage 1: RO7490677 10 mg/kg IV Every Week (QW)Main Phase Stage 1: RO7490677 10 mg/kg IV Every 4 Weeks (Q4W)Main Phase Stage 1: RO7490677 10 mg/kg IV QW + RuxolitinibMain Phase Stage 1: RO7490677 10 mg/kg IV Q4W+ RuxolitinibMain Phase Stage 2: RO7490677 0.3 mg/kg IV Q4WMain Phase Stage 2: RO7490677 3 mg/kg IV Q4WMain Phase Stage 2: RO7490677 10 mg/kg IV Q4WTotal
Female5235———15
Male3531———12
Sex: Female, Male
Sex: Female, Male(Participants)Main Phase Stage 1: RO7490677 10 mg/kg IV Every Week (QW)Main Phase Stage 1: RO7490677 10 mg/kg IV Every 4 Weeks (Q4W)Main Phase Stage 1: RO7490677 10 mg/kg IV QW + RuxolitinibMain Phase Stage 1: RO7490677 10 mg/kg IV Q4W+ RuxolitinibMain Phase Stage 2: RO7490677 0.3 mg/kg IV Q4WMain Phase Stage 2: RO7490677 3 mg/kg IV Q4WMain Phase Stage 2: RO7490677 10 mg/kg IV Q4WTotal
Female————1681135
Male————17242162
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Main Phase Stage 1: RO7490677 10 mg/kg IV Every Week (QW)Main Phase Stage 1: RO7490677 10 mg/kg IV Every 4 Weeks (Q4W)Main Phase Stage 1: RO7490677 10 mg/kg IV QW + RuxolitinibMain Phase Stage 1: RO7490677 10 mg/kg IV Q4W+ RuxolitinibMain Phase Stage 2: RO7490677 0.3 mg/kg IV Q4WMain Phase Stage 2: RO7490677 3 mg/kg IV Q4WMain Phase Stage 2: RO7490677 10 mg/kg IV Q4WTotal
Hispanic or Latino0010———1
Not Hispanic or Latino8746———25
Unknown or Not Reported0010———1
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Main Phase Stage 1: RO7490677 10 mg/kg IV Every Week (QW)Main Phase Stage 1: RO7490677 10 mg/kg IV Every 4 Weeks (Q4W)Main Phase Stage 1: RO7490677 10 mg/kg IV QW + RuxolitinibMain Phase Stage 1: RO7490677 10 mg/kg IV Q4W+ RuxolitinibMain Phase Stage 2: RO7490677 0.3 mg/kg IV Q4WMain Phase Stage 2: RO7490677 3 mg/kg IV Q4WMain Phase Stage 2: RO7490677 10 mg/kg IV Q4WTotal
American Indian or Alaska Native0010———1
Asian0010———1
Native Hawaiian or Other Pacific Islander0000———0
Black or African American1010———2
White7736———23
More than one race0000———0
Unknown or Not Reported0000———0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Main Phase Stage 1: RO7490677 10 mg/kg IV Every Week (QW)Main Phase Stage 1: RO7490677 10 mg/kg IV Every 4 Weeks (Q4W)Main Phase Stage 1: RO7490677 10 mg/kg IV QW + RuxolitinibMain Phase Stage 1: RO7490677 10 mg/kg IV Q4W+ RuxolitinibMain Phase Stage 2: RO7490677 0.3 mg/kg IV Q4WMain Phase Stage 2: RO7490677 3 mg/kg IV Q4WMain Phase Stage 2: RO7490677 10 mg/kg IV Q4WTotal
American Indian or Alaska Native————0000
Asian————0123
Native Hawaiian or Other Pacific Islander————0000
Black or African American————0101
White————33292991
More than one race————0000
Unknown or Not Reported————0112
08

Study locations

23 sites
  • Mayo Clinic Cancer Center
    Phoenix, Arizona 85054, United States
  • Stanford Cancer Institute
    Palo Alto, California 94304, United States
  • Emory Hospital
    Atlanta, Georgia 30322, United States
  • University of Maryland Medical Center
    Baltimore, Maryland 21201, United States
  • Dana-Farber Cancer Institute
    Boston, Massachusetts 02215, United States
  • University of Michigan
    Ann Arbor, Michigan 48109-2800, United States
  • Mount Sinai Medical Center
    New York, New York 10029, United States
  • Weill Cornell Medical Center
    New York, New York 10065, United States
  • Wake Forest Baptist Medical Center
    Winston-Salem, North Carolina 27157, United States
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37232, United States
  • MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • Providence Health Care
    Vancouver, British Columbia V6Z 2A5, Canada
  • The Princess Margaret Cancer Centre
    Toronto, Ontario M5T 2M9, Canada
  • Hospital Saint-Louis
    Paris, 75475, France
  • University Medical Center RWTH Aachen
    Aachen, D-52074, Germany
  • Johannes Wesling Academic Medical Center
    Minden, 32429, Germany
  • Hadassah Medical Centre
    Jerusalem, 91120, Israel
  • Meir Medical Centre
    Kfar Saba, 4428164, Israel
  • Fondazione IRCCS Policlinico San Matteo
    Pavia, 27100, Italy
  • Marche Nord Hospital
    Pesaro, 61122, Italy
  • Erasmus Medical Center
    Rotterdam, Zuid Holland 3015 CE, Netherlands
  • Radboud University Medical Center
    Nijmegen, 6525 GA, Netherlands
  • Guy's and St. Thomas' Hospital
    London, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2013 to primary completion in Jul 2020, 81 months.

Results were first posted in Jan 2022, 1 year 5 months after primary completion.

Of 30 industry-sponsored phase 2 interventional studies under Primary Myelofibrosis, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 66. This study's 81 months is above that.

Counting every sponsor, half of 97 studies reached it within 66 months; a quarter within 32 and three quarters within 111.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 29, 2013
First posted
Nov 13, 2013
StartActual
Oct 1, 2013
Primary completionActual
Jul 10, 2020
CompletionActual
Jul 10, 2020
Results first posted
Jan 5, 2022
Last update
Jan 5, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 5, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01981850
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Nov 13, 2013
Start date
Oct 1, 2013
Primary completion
Jul 10, 2020
Completion
Jul 10, 2020
Results posted
Jan 5, 2022
Last update
Jan 5, 2022

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: PRM-151

Start the discussion